Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.37 |
| ▸ | EBP | Q15125 | 1/20 | 0.35 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CTRC | Q99895 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7649155 | 0.88 | MEN1 (0.39) | F2F10PRSS2ALDH1A1CTRC | |
| SCHEMBL6925569 | 0.85 | ALDH1A1 (0.41) | F2F10PRSS2KDM4EALDH1A1 | |
| SCHEMBL6749826 | 0.83 | F2 (0.47) | F2F10PRSS2KDM4EALDH1A1 | |
| SCHEMBL6926978 | 0.77 | F2 (0.37) | F2F10PRSS2EBPDHCR7 | |
| SCHEMBL6930340 | 0.77 | TSHR (0.45) | KDM4EALDH1A1 | |
| SCHEMBL6749829 | 0.77 | F2 (0.41) | F2F10PRSS2CTRC | |
| SCHEMBL6747717 | 0.76 | SMN1; SMN2 (0.37) | F2PRSS2ALDH1A1CTRC | |
| SCHEMBL7647063 | 0.75 | F2 (0.46) | F2F10PRSS2CTRC | |
| SCHEMBL6745715 | 0.74 | F2 (0.50) | F2F10PRSS2CTRC | |
| Hydrochloric Acid SCHEMBL7652508 | 0.73 | F2 (0.45) | F2F10PRSS2CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518310-B2 | Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | F2 32/4885F10 76/4885PRSS2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.